

**Minutes of the HSE Directorate meeting
Wednesday, 1st June, 2016**

Directorate Members Present: T. O'Brien (Chairman), S. Mulvany, L. Woods, A. O'Connor, S. O'Keeffe, J. Hennessy, P. Healy and P. Crowley

Apologies: D. Purcell

In attendance R. Mitchell (Secretary)

Joined the Meeting: S. O'Reilly, Chairperson, HSE Drugs Group and S. Flanagan, Chief Pharmacist, HSE Corporate Pharmaceutical Unit

Time & Location: Room 1.11, Dr. Steevens' Hospital, Dublin 8 at 3.30pm

Item	Discussion / Comments	Action
1	Report from HSE Drugs Committee	
	<p>S. O'Reilly and S. Flanagan briefed the Directorate on the Drugs Group's consideration and recommendation in relation to the drug Pembrolizumab for malignant melanoma. The Drugs Group recommended funding Pembrolizumab for monotherapy for metastatic melanoma and also recommended funding as monotherapy for second line therapy post Ipilimumab. They also recommended that second line use of Ipilimumab post Pembrolizumab will not be reimbursed except in circumstances where patients are either unable to tolerate Pembrolizumab or are part of the existing cohort who have failed Pembrolizumab. The Group also recommended to the National Cancer Control Programme (NCCP) that they establish a medical oncology expert advisory group to advise on sequencing and combinations of treatment for advanced melanoma. A lengthy discussion followed including questions and clarifications from members of the Directorate.</p> <p>S. O'Reilly and S. Flanagan left the meeting here.</p> <p>Following consideration of the briefing and recommendation from the Drugs Group the Directorate decided to accept the Group's recommendation subject to the NCCP having the necessary funding to cover the costs as outlined in the briefing and that there would be a three week lead-in time to implementation of the decision. It was also agreed that the HSE would advise the Department of Health and the Department of Expenditure and Reform of its decision.</p>	NCCP
2	Service Plan 2017	
	The Directorate considered the Service Plan process for 2017. The Chief Financial Officer and interim Deputy Director General advised that the DoH would be looking for a first view in July, on 2017. It was agreed that it was not necessary for Divisions to seek service bids from CHO's or Hospital Groups as we have already gathered that information. Neither was it necessary for National Divisions to issue templates to the services for ELS as that information is also available at national division level. It was agreed therefore that the National Divisions should be in a position to supply to the DoH from existing information when requested (likely July) the ELS together with any proposed service developments as a first view for 2017.	CFO/QAV and National Divisions
3	Any Other Business	
	No matters were raised under this item	

The meeting concluded at 5pm

Signed:

Date:

Tony O'Brien
Chairman